JP6456823B2 - 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体 - Google Patents

疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体 Download PDF

Info

Publication number
JP6456823B2
JP6456823B2 JP2015523576A JP2015523576A JP6456823B2 JP 6456823 B2 JP6456823 B2 JP 6456823B2 JP 2015523576 A JP2015523576 A JP 2015523576A JP 2015523576 A JP2015523576 A JP 2015523576A JP 6456823 B2 JP6456823 B2 JP 6456823B2
Authority
JP
Japan
Prior art keywords
charom
arom
mmol
pain
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015523576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522650A5 (OSRAM
JP2015522650A (ja
Inventor
ピエール、ソコロフ
フレデリック、カシュー
Original Assignee
ピエール、ファーブル、メディカマン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエール、ファーブル、メディカマン filed Critical ピエール、ファーブル、メディカマン
Publication of JP2015522650A publication Critical patent/JP2015522650A/ja
Publication of JP2015522650A5 publication Critical patent/JP2015522650A5/ja
Application granted granted Critical
Publication of JP6456823B2 publication Critical patent/JP6456823B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015523576A 2012-07-27 2013-07-29 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体 Active JP6456823B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305922.2A EP2689778A1 (en) 2012-07-27 2012-07-27 Derivatives of azaindoles or diazaindoles for treating pain
EP12305922.2 2012-07-27
PCT/EP2013/065907 WO2014016433A1 (en) 2012-07-27 2013-07-29 Derivatives of azaindazole or diazaindazole type for treating pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018200317A Division JP6732855B2 (ja) 2012-07-27 2018-10-24 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体

Publications (3)

Publication Number Publication Date
JP2015522650A JP2015522650A (ja) 2015-08-06
JP2015522650A5 JP2015522650A5 (OSRAM) 2016-09-15
JP6456823B2 true JP6456823B2 (ja) 2019-01-23

Family

ID=48948392

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015523576A Active JP6456823B2 (ja) 2012-07-27 2013-07-29 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体
JP2018200317A Active JP6732855B2 (ja) 2012-07-27 2018-10-24 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018200317A Active JP6732855B2 (ja) 2012-07-27 2018-10-24 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体

Country Status (28)

Country Link
US (1) US9381195B2 (OSRAM)
EP (2) EP2689778A1 (OSRAM)
JP (2) JP6456823B2 (OSRAM)
KR (1) KR102120505B1 (OSRAM)
CN (1) CN104684554B (OSRAM)
AU (1) AU2013294920B2 (OSRAM)
BR (1) BR112015001502B1 (OSRAM)
CA (1) CA2879595C (OSRAM)
CY (1) CY1118478T1 (OSRAM)
DK (1) DK2877177T3 (OSRAM)
ES (1) ES2612349T3 (OSRAM)
HR (1) HRP20170104T1 (OSRAM)
HU (1) HUE032919T2 (OSRAM)
IL (1) IL236917A (OSRAM)
LT (1) LT2877177T (OSRAM)
MA (1) MA37866B1 (OSRAM)
MX (1) MX363605B (OSRAM)
MY (1) MY183398A (OSRAM)
NZ (1) NZ705253A (OSRAM)
PL (1) PL2877177T3 (OSRAM)
PT (1) PT2877177T (OSRAM)
RS (1) RS55646B1 (OSRAM)
RU (1) RU2640046C2 (OSRAM)
SI (1) SI2877177T1 (OSRAM)
TN (1) TN2015000034A1 (OSRAM)
UA (1) UA116107C2 (OSRAM)
WO (1) WO2014016433A1 (OSRAM)
ZA (1) ZA201501209B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019031542A (ja) * 2012-07-27 2019-02-28 ピエール、ファーブル、メディカマン 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2918588B1 (en) 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
AU2015328307B2 (en) 2014-10-06 2019-11-21 Apm Therapeutics 1, Inc. Triazolopyridine compounds and methods for the treatment of cystic fibrosis
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法
MX386416B (es) 2016-04-04 2025-03-18 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE063877T2 (hu) 2016-05-18 2024-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018079759A1 (ja) * 2016-10-31 2018-05-03 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する縮合複素環および縮合炭素環誘導体
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20220259199A1 (en) * 2018-05-02 2022-08-18 Jw Pharmaceutical Corporation Novel heterocycle derivative
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
CN110105356B (zh) * 2019-05-31 2022-04-01 四川国康药业有限公司 一种氮杂吲哚类化合物及其制备方法和用途
TW202448883A (zh) * 2023-05-24 2024-12-16 大陸商長春金賽藥業有限責任公司 Ｆｇｆｒ２／３選擇性抑制劑、藥物組合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2283961A1 (en) 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
HUP0301183A3 (en) 2000-06-22 2006-02-28 Pfizer Process for the preparation of pyrazolopyrimidinones
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
KR101011957B1 (ko) * 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
SI2120932T1 (sl) * 2006-12-20 2014-09-30 Nerviano Medical Sciences S.R.L. Indazolni derivati kot kinazni inhibitorji za zdravljenje raka
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
PL2176231T3 (pl) * 2007-07-20 2017-04-28 Nerviano Medical Sciences S.R.L. Podstawione pochodne indazolu aktywne jako inhibitory kinazy
EP2373626B1 (en) 2008-12-18 2016-08-24 Nerviano Medical Sciences S.r.l. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019031542A (ja) * 2012-07-27 2019-02-28 ピエール、ファーブル、メディカマン 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体

Also Published As

Publication number Publication date
DK2877177T3 (en) 2017-02-06
IL236917A (en) 2016-11-30
MX2015001009A (es) 2015-06-04
TN2015000034A1 (en) 2016-06-29
EP2877177A1 (en) 2015-06-03
WO2014016433A1 (en) 2014-01-30
EP2689778A1 (en) 2014-01-29
KR102120505B1 (ko) 2020-06-08
US9381195B2 (en) 2016-07-05
US20150190394A1 (en) 2015-07-09
CN104684554A (zh) 2015-06-03
CA2879595A1 (en) 2014-01-30
HRP20170104T1 (hr) 2017-03-24
BR112015001502B1 (pt) 2023-03-07
JP2019031542A (ja) 2019-02-28
HK1207302A1 (en) 2016-01-29
KR20150038295A (ko) 2015-04-08
EP2877177B1 (en) 2016-10-26
MA37866B1 (fr) 2016-12-30
PL2877177T3 (pl) 2017-04-28
PT2877177T (pt) 2017-02-06
HUE032919T2 (hu) 2017-11-28
JP2015522650A (ja) 2015-08-06
RS55646B1 (sr) 2017-06-30
LT2877177T (lt) 2017-01-25
SI2877177T1 (sl) 2017-02-28
CN104684554B (zh) 2017-05-10
AU2013294920A1 (en) 2015-03-12
AU2013294920B2 (en) 2017-08-24
RU2640046C2 (ru) 2017-12-26
BR112015001502A2 (pt) 2017-07-04
JP6732855B2 (ja) 2020-07-29
MX363605B (es) 2019-03-26
MY183398A (en) 2021-02-18
NZ705253A (en) 2017-05-26
MA37866A1 (fr) 2016-05-31
CY1118478T1 (el) 2017-07-12
ZA201501209B (en) 2016-03-30
RU2015106434A (ru) 2016-09-20
CA2879595C (en) 2020-07-28
ES2612349T3 (es) 2017-05-16
UA116107C2 (uk) 2018-02-12

Similar Documents

Publication Publication Date Title
JP6732855B2 (ja) 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体
JP5931926B2 (ja) 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体
US9428510B2 (en) Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk
HK1207302B (en) Derivatives of azaindazole or diazaindazole type for treating pain
OA17324A (en) Derivatives of azaindazole or diazaindazole type for treating pain.
OA16493A (en) Derivatives of azaindazole or diazaindazole type as medicament.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181219

R150 Certificate of patent or registration of utility model

Ref document number: 6456823

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250